Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 531

1.

Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults.

Metlay JP, Fishman NO, Joffe M, Edelstein PH.

Vaccine. 2006 Jan 23;24(4):468-75. Epub 2005 Aug 15.

PMID:
16125826
2.

Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B.

Pediatr Infect Dis J. 2004 Jun;23(6):485-9.

PMID:
15194827
3.

[Bacteremic pneumococcal pneumonia].

Pineda Solas V, Pérez Benito A, Domingo Puiggros M, Larramona Carrera H, Segura Porta F, Fontanals Aymerich D.

An Esp Pediatr. 2002 Nov;57(5):408-13. Spanish.

PMID:
12467543
4.

Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.

Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.

Clin Infect Dis. 2008 Aug 15;47(4):476-84. doi: 10.1086/590001.

PMID:
18627249
5.

Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England.

Foster D, Knox K, Walker AS, Griffiths DT, Moore H, Haworth E, Peto T, Brueggemann AB, Crook DW; Oxford Invasive Pneumococcal Surveillance Group..

J Med Microbiol. 2008 Apr;57(Pt 4):480-7. doi: 10.1099/jmm.0.47690-0.

PMID:
18349369
6.

[Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].

Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A, Santana M, Lafarga B.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):14-21. doi: 10.1016/j.eimc.2008.03.001. Epub 2009 Jan 9. Spanish.

PMID:
19217998
7.

Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine.

Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW, Buck GE.

Pediatr Infect Dis J. 2005 Apr;24(4):320-3.

PMID:
15818291
8.

Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.

Albrich WC, Baughman W, Schmotzer B, Farley MM.

Clin Infect Dis. 2007 Jun 15;44(12):1569-76. Epub 2007 May 8.

PMID:
17516400
9.

Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.

Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP.

Pediatr Infect Dis J. 2007 Sep;26(9):771-7.

PMID:
17721369
11.

Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.

Ho PL, Chiu SS, Chow FK, Mak GC, Lau YL.

Vaccine. 2007 Sep 28;25(39-40):6837-41. Epub 2007 Aug 7.

PMID:
17714837
12.

The epidemiology of invasive pneumococcal disease in children in Far North Queensland.

Fagan RL, Hanna JN, Messer RD, Brookes DL, Murphy DM.

J Paediatr Child Health. 2001 Dec;37(6):571-5.

PMID:
11903838
13.

Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona.

Pérez A, Sala P, Giménez M, Sierra M, Esteve A, Alonso A, Quesada M, Raspall F, Ausina V, Rodrigo C.

Eur J Clin Microbiol Infect Dis. 2004 Sep;23(9):677-81. Epub 2004 Aug 18.

PMID:
15322935
14.

Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8.

15.

The potential of pneumococcal conjugate vaccines for children.

Whitney CG, Pickering LK.

Pediatr Infect Dis J. 2002 Oct;21(10):961-70. Review.

PMID:
12394822
16.

Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations.

Adam D, Fehnle K.

Vaccine. 2008 Nov 5;26(47):5944-51. doi: 10.1016/j.vaccine.2008.08.058. Epub 2008 Sep 16.

PMID:
18801402
17.

Herd immunity and pneumococcal conjugate vaccine: a quantitative model.

Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, Orenstein W, Stephens DS.

Vaccine. 2007 Jul 20;25(29):5390-8. Epub 2007 May 22.

PMID:
17583392
18.

Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.

Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM.

Pediatrics. 2008 Mar;121(3):562-9. doi: 10.1542/peds.2007-0018.

PMID:
18310206
19.

Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.

Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A.

Vaccine. 2009 Jun 24;27(31):4136-41. doi: 10.1016/j.vaccine.2009.04.057. Epub 2009 May 9.

PMID:
19406190
20.

Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use.

Pilishvili T, Zell ER, Farley MM, Schaffner W, Lynfield R, Nyquist AC, Vazquez M, Bennett NM, Reingold A, Thomas A, Jackson D, Schuchat A, Whitney CG.

Pediatrics. 2010 Jul;126(1):e9-17. doi: 10.1542/peds.2009-2150. Epub 2010 Jun 14.

PMID:
20547641

Supplemental Content

Support Center